Danny Rischin

Q: What Schools Are Affiliated With Danny Rischin

Danny Rischin is affiliated with the following schools: University of Texas Southwestern Medical Center, Chulalongkorn University, University of Queensland, Osaka Metropolitan University, MD Anderson Cancer Center, University of Oxford, University of Melbourne

Danny Rischin's AcademicInfluence.com Rankings

Danny Rischin

Philosophy

#9388

World Rank

#12941

Historical Rank

Logic

#6367

World Rank

#7879

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Danny Rischin's Degrees

Bachelors Medicine University of Melbourne
PhD Cancer Biology University of Melbourne

Why Is Danny Rischin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Danny Rischin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (2003) (2937)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (2019) (1244)
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. (2002) (835)
PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma (2018) (807)
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. (2010) (692)
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. (2010) (656)
Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. (2006) (534)
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. (2002) (516)
Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. (2003) (433)
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. (2010) (349)
Head and Neck Squamous Cell Carcinoma (2020) (336)
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. (2005) (304)
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. (2009) (298)
Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. (1996) (256)
Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer (2005) (253)
Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). (2005) (251)
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. (2018) (235)
IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer (2011) (225)
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. (2010) (225)
High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07. (2003) (214)
An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. (2005) (213)
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. (2020) (212)
F‐18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma (2001) (210)
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. (2012) (203)
Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. (2001) (202)
The 'QUAD SHOT'--a phase II study of palliative radiotherapy for incurable head and neck cancer. (2005) (195)
Phase II study of imatinib in patients with small cell lung cancer. (2003) (183)
Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. (2004) (169)
Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? (2006) (166)
Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. (2005) (156)
Clinical impact of, and prognostic stratification by, F‐18 FDG PET/CT in head and neck mucosal squamous cell carcinoma (2007) (150)
Prospective study of percutaneous endoscopic gastrostomy tubes versus nasogastric tubes for enteral feeding in patients with head and neck cancer undergoing (chemo)radiation (2009) (150)
Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent (2005) (142)
Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. (2002) (136)
KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2018) (128)
Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study (2010) (123)
N2‐N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders—Results of Trans Tasman Radiation Oncology Group Study 98.02 (2008) (118)
Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma (2004) (116)
Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation (2008) (114)
Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. (2018) (114)
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2019) (111)
Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial. (2018) (104)
Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. (1998) (99)
Impact of Positron Emission Tomography on the Management of Patients With Small-Cell Lung Cancer: Preliminary Experience (2004) (99)
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition (2016) (99)
Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. (2003) (98)
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors (2010) (92)
The usefulness of fluorine 18–labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor (2003) (90)
Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus (2020) (88)
Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer (2013) (85)
Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma (2011) (84)
Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma (2018) (83)
Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. (1997) (81)
Survival with Cemiplimab in Recurrent Cervical Cancer. (2022) (80)
Paranasal sinus tumors: Peter maccallum cancer institute experience (2004) (80)
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing (2020) (79)
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) (2016) (77)
Usefulness of fluorine‐18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck (2004) (75)
Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. (1996) (74)
How do oncologists deal with incidental abnormalities on whole‐body fluorine‐18 fluorodeoxyglucose PET/CT? (2007) (70)
Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study (2007) (69)
Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. (1999) (69)
What is the best treatment for patients with human papillomavirus–positive and –negative oropharyngeal cancer? (2014) (68)
Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR) (2000) (68)
A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients. (2002) (65)
Imaging of hypoxia with 18F‐FAZA PET in patients with locally advanced non‐small cell lung cancer treated with definitive chemoradiotherapy (2013) (63)
Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. (2002) (61)
Frequency and prognostic significance of p16INK4A protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma (2015) (60)
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. (2015) (59)
Optimising the therapeutic ratio in head and neck cancer. (2010) (58)
Role of FDG-PET/CT in staging and follow-up of head and neck squamous cell carcinoma. (2011) (58)
Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome (2014) (58)
Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced head and neck cancer. (2000) (57)
Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. (1996) (57)
Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. (2011) (57)
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. (2003) (56)
Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer (2012) (55)
Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute. (1996) (55)
Merkel cell carcinoma: emerging biology, current approaches, and future directions. (2015) (55)
High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience. (2009) (51)
Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. (2008) (50)
Oropharyngeal cancer, human papilloma virus, and clinical trials. (2010) (49)
De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies (2020) (48)
Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. (2018) (47)
Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274). (2021) (47)
Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial (2011) (47)
Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation (2011) (45)
Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. (2002) (45)
Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. (2011) (45)
Analysis of toxicity of Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group study. (2001) (43)
Weekly carboplatin reduces toxicity during synchronous chemoradiotherapy for Merkel cell carcinoma of skin. (2008) (43)
Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial. (2009) (42)
FDG-PET-Detected Extracranial Metastasis in Patients with Non-Small Cell Lung Cancer Undergoing Staging for Surgery or Radical Radiotherapy (2003) (41)
A randomised crossover trial of chemotherapy in the home: patient preferences and cost anaiysis (2000) (41)
Radiation recall reaction following gemcitabine. (2001) (41)
Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. (2007) (40)
Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). (2017) (39)
Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose. (2013) (38)
Prospective trial to evaluate staged neck dissection or elective neck radiotherapy in patients with CT‐staged T1‐2 N0 squamous cell carcinoma of the oral tongue (2009) (38)
Randomised trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01) - a Trans-Tasman Radiation Oncology Group study. (2021) (38)
Phase I trial of cremophor EL with bolus doxorubicin. (1998) (37)
Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma. (2004) (37)
Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. (2001) (37)
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. (2020) (36)
Tonsillar cancer: The Peter MacCallum experience with unilateral and bilateral irradiation (2014) (36)
BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma. (2016) (36)
Overview of Advances in Head and Neck Cancer. (2015) (36)
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study (2020) (36)
A phase II trial of ZD0473 in platinum-pretreated ovarian cancer. (2002) (36)
Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial (2005) (36)
Suboptimal health literacy in patients with lung cancer or head and neck cancer (2013) (36)
Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide (1997) (34)
Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line (1999) (34)
Prospective analysis of the utility of 18‐FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03 (2018) (33)
Timely initiation of chemotherapy: a systematic literature review of six priority cancers – results and recommendations for clinical practice (2017) (33)
The role of human papillomavirus in p16‐positive oral cancers (2018) (33)
p16‐positive lymph node metastases from cutaneous head and neck squamous cell carcinoma: No association with high‐risk human papillomavirus or prognosis and implications for the workup of the unknown primary (2016) (32)
Correlation of p16 status, hypoxic imaging using [18F]‐misonidazole positron emission tomography and outcome in patients with loco‐regionally advanced head and neck cancer (2014) (32)
Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome. (2013) (31)
Relapse patterns in WHO 2/3 nasopharyngeal cancer: is there a difference between ethnic Asian vs. non-Asian patients? (2006) (31)
Phase 1 Study of Tirapazamine in Combination With Radiation and Weekly Cisplatin in Patients With Locally Advanced Cervical Cancer (2010) (30)
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. (2022) (30)
A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis (2001) (30)
Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients (2004) (29)
Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison. (1998) (29)
A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. (2013) (29)
Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up. (2020) (28)
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis (2021) (28)
Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial (2010) (28)
Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer. (2004) (28)
The utility of PET/CT in staging and assessment of treatment response of nasopharyngeal cancer (2011) (27)
Strategies to overcome accelerated repopulation and hypoxia--what have we learned from clinical trials? (2004) (27)
A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. (2000) (27)
Individualised mindfulness‐based stress reduction for head and neck cancer patients undergoing radiotherapy of curative intent: a descriptive pilot study (2017) (27)
Frequency and prognostic significance of p16 INK4A protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma (2015) (27)
Recent Insights and Advances in the Management of Merkel Cell Carcinoma. (2016) (27)
Association of acquired Pelger‐Huet anomaly with taxoid therapy (1996) (27)
Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (2008) (27)
Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01. (2007) (26)
A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck (2007) (26)
The impact of preradiation residual disease volume on time to locoregional failure in cutaneous Merkel cell carcinoma--a TROG substudy. (2013) (26)
A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174). (2014) (26)
Non-smoking, non-drinking elderly females, a 5 year follow-up of a clinically distinct cohort of oral squamous cell carcinoma patients. (2018) (26)
Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up. (2019) (25)
Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC). (2019) (25)
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. (2020) (25)
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score (2022) (25)
The Utility of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography in the Investigation of Patients with Disseminated Carcinoma of Unknown Primary Origin (2005) (24)
Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. (2011) (23)
Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer (2010) (23)
Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer (2014) (23)
Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer. (2012) (23)
18F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data (2015) (22)
PRISM: Phase 2 trial with panitumumab monotherapy as second‐line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (2016) (22)
Quantitative and qualitative analysis of [18F]FDG and [18F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome (2016) (21)
Impact of center size and experience on outcomes in head and neck cancer. (2015) (21)
Developing a performance data suite to facilitate lean improvement in a chemotherapy day unit. (2013) (21)
Sinonasal malignancies of neuroendocrine origin. (2008) (20)
Diabetes associated with immune checkpoint inhibition: presentation and management challenges (2018) (20)
A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. (2004) (20)
Quality of Life, Toxicity and Unmet Needs in Nasopharyngeal Cancer Survivors (2020) (20)
Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature (2001) (20)
Treatment response in the neck: p16+ versus p16− oropharyngeal cancer (2013) (19)
T4 squamous cell carcinoma of the oral tongue without mandibular involvement: surgery or chemoradiotherapy? (2014) (19)
PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy. (2005) (19)
Safety and cost analysis of an (18)FDG-PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation. (2015) (19)
Oral cyclophosphamide in recurrent ovarian cancer (2016) (19)
Phase 1 study of a focal adhesion kinase (FAK) inhibitor PF-00562271 in patients (pts) with advanced solid tumors (2007) (19)
Abiraterone in metastatic salivary duct carcinoma. (2015) (19)
Promising Results of a Cooperative Group Phase II Trial of Preoperative Chemoradiation for Locally Advanced Rectal Cancer (TROG 9801) (2005) (19)
Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome (2014) (18)
The role of PET-CT in the management of patients with advanced cancer of the head and neck (2008) (18)
Rectal Adenocarcinoma With Germ Cell Elements Treated With Chemotherapy (1993) (18)
Subxiphoid partial pericardiectomy with or without sclerosant instillation in the treatment of symptomatic pericardial effusions in patients with malignancy (1991) (17)
Larynx preservation for patients with locally advanced laryngeal cancer. (2013) (17)
Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC) (2019) (17)
A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC (2005) (16)
Elusive goal of targeting tumor hypoxia for therapeutic gain. (2012) (16)
Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer. (2003) (16)
Docetaxel effectively mobilizes peripheral blood CD34+ cells (2000) (16)
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. (1999) (16)
Combined modality treatment for locally advanced squamous-cell carcinoma of the oropharynx in a woman with Bloom's syndrome: a case report and review of the literature. (2001) (16)
Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck. (2000) (16)
Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the delivery of postoperative radiation therapy in complex cutaneous squamous cell carcinoma of the head and neck (cSCCHN). (2020) (16)
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses (2020) (15)
ZD0473 phase II monotherapy trial in second-line ovarian cancer (2001) (15)
KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). (2020) (15)
Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics. (2002) (15)
986ORANDOMIZED PHASE II STUDY OF MEHD7945A (MEHD) VS CETUXIMAB (CET) IN >= 2ND-LINE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD & NECK (RMSCCHN) PROGRESSIVE ON/AFTER PLATINUM-BASED CHEMOTHERAPY (PTCT). (2014) (15)
A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669. (2018) (14)
Parotid-sparing radiotherapy: does it really reduce xerostomia? (2005) (14)
Identification of an excellent prognosis subset of human papillomavirus associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance. (2019) (14)
Carboplatin Dosing in Ovarian Cancer: Problems and Pitfalls (2011) (13)
CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy. (2002) (13)
Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy. (2002) (13)
Larynx preservation with primary non‐surgical treatment for loco‐regionally advanced larynx cancer (2011) (13)
A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies (2018) (13)
Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis (2020) (13)
Validation and characterisation of prognostically significant PD-L1+ immune cells in HPV+ oropharyngeal squamous cell carcinoma. (2019) (13)
KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). (2017) (13)
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study (2022) (13)
8 Extraordinary tumor control in phase I trial of concurrent tirapazamine cisplatin and radiotherapy for far advanced head and neck cancer (1999) (12)
Radiation with cisplatin or carboplatin for locally advanced cervix cancer: The experience of a tertiary cancer centre (2013) (12)
Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance. (2019) (11)
Prolonged remission in a patient with nasopharyngeal carcinoma with a solitary bone metastasis. (2011) (11)
INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors. (2017) (11)
Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer (1999) (11)
Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval. (2002) (11)
Fear of Cancer Recurrence in Survivors of Human Papillomavirus-Associated Oropharyngeal Carcinoma. (2021) (11)
A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL. (2012) (10)
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study (2000) (10)
Multidrug resistance in leukemia. (1993) (10)
Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC) (2019) (10)
Weekly cisplatin and radiotherapy for low risk, locoregionally advanced human papillomavirus–positive oropharyngeal squamous cell carcinoma (2016) (10)
Ovarian Growing Teratoma Syndrome With Spuriously Elevated α-Fetoprotein. (2015) (10)
Phase II Trial of Continuous Infusion Carboplatin, 5-Fluorouracil, and Radiotherapy for Localized Cancer of the Esophagus (2002) (10)
Unilateral radiotherapy treatment for p16/human papillomavirus–positive squamous cell carcinoma of unknown primary in the head and neck (2018) (10)
Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services (2016) (10)
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and GM-CSF in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. (2021) (9)
Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC). (2020) (9)
A phase II trial of paclitaxel and epirubicin in advanced breast cancer (2000) (9)
Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial. (2020) (9)
A randomised trial of dexamethasone, lorazepam and prochlorperazine for emesis in patients receiving chemotherapy. (1992) (9)
Review : Cremophor: Pharmacological activity of an "inert" solubiliser (1997) (9)
Post-operative concurrent chemo-radiotherapy versus post-operative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: A randomized phase III trial (Trans Tasman Radiation Oncology Group 05.01 Trial; POST study). (2017) (9)
Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma. (2012) (9)
Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation (2017) (8)
Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). (2020) (8)
Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study. (2001) (8)
Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas (2015) (8)
LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) (2022) (8)
INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors. (2020) (7)
The local-regionally advanced nasopharyngeal carcinoma jigsaw puzzle: where does the chemotherapy piece fit? (2002) (7)
Intraperitoneal distribution imaging in ovarian cancer patients (2011) (7)
Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis (2015) (7)
Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centre (2020) (7)
Efficacy of erlotinib in patients with advanced Non‐small‐cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study (2012) (7)
Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer. (1997) (7)
Clinical verification of the superiority of the current International Union Against Cancer staging criteria in an Australian population of patients with nasopharyngeal carcinoma. (2004) (7)
Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC). (2018) (7)
Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinoma (2020) (7)
'Boomerang' technique: an improved method for conformal treatment of locally advanced nasopharyngeal cancer. (2004) (7)
Calculating carboplatin doses using the 4-variable modification of diet in renal disease (4-v MDRD) estimate of glomerular filtration rate (GFR) in the Calvert formula (2007) (7)
Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin. (2017) (7)
Phase I trial of cremophor EL and doxorubicin in advanced cancer: 100 (1994) (7)
Intensity-modulated radiotherapy: examples of its utility in head and neck cancer. (2004) (7)
Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre (2018) (7)
Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors (2017) (6)
Health-Related Quality of Life, Psychosocial Distress and Unmet Needs in Older Patients With Head and Neck Cancer (2022) (6)
Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG. (2017) (6)
A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC). (2020) (6)
Quantitative and qualitative analysis of [ 18 F]FDG and [ 18 F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome (2018) (6)
Impact of histological Oral Tongue Cancer margins on locoregional recurrence: A multi-centre retrospective analysis. (2020) (6)
Randomized trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01): A Trans-Tasman Radiation Oncology Group study. (2021) (6)
A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy (2004) (6)
Induction chemotherapy in head and neck cancer: closer to an answer? (2011) (6)
Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study. (2018) (6)
FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma (2021) (6)
Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care. (2020) (6)
Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (2018) (5)
Patient-reported quality of life and symptom burden measures in human papillomavirus associated oropharyngeal cancer - A review of the literature and PRO methodology. (2021) (5)
High-Dose Cisplatin for Head and Neck Cancer Lives On. (2018) (5)
First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1. (2018) (5)
First-in-man trial of 4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid (PENAO) as a continuous intravenous infusion (CIVI), in patients (pt) with advanced solid tumours. (2016) (5)
GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer. (2018) (5)
Merkel cell carcinoma – current therapeutic options (2003) (5)
Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis (2021) (5)
Superiority of tirapazamine-containing chemoradiation in head and neck cancers showing evidence of hypoxia on 18F-misonidazole (FMISO) pet scanning (2004) (5)
915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (2020) (5)
Comparison of neutropenia in a randomized, crossover trial of 3-, 6-, and 24-h infusions of paclitaxel. (2003) (5)
KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC). (2018) (5)
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (2021) (5)
Does biomodulation of 5-fluorouracil improve results? (1999) (5)
Hypocalcemia associated with bone metastases in a patient with salivary-gland carcinoma (2006) (4)
Sexual Health and Interpersonal Relationships Following Chemoradiotherapy For Human Papillomavirus Associated Oropharyngeal Cancer : a cross-sectional study. (2020) (4)
Cancer Therapy : Clinical IL 6-STAT 3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer (2011) (4)
Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II). (1996) (4)
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. (2022) (4)
Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts. (2018) (4)
Long‐term survival following chemoradiation for inoperable non‐small cell lung cancer (2008) (4)
Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma (2022) (4)
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103) (2018) (4)
Phase I, pharmacokinetic, and pharmacodynamic evaluation of BNC105P, a novel anticancer agent that is both a vascular disrupting agent (VDA) and an inhibitor of cancer cell proliferation. (2009) (4)
1O Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC) (2020) (4)
Prechemotherapy hepatitis B virus (HBV) screening in medical oncology patients: A national survey. (2010) (4)
Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies (2019) (4)
Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial - A Trans-Tasman Radiation Oncology Group study. (2020) (4)
Further clinical interpretation and implications of KEYNOTE-048 findings – Authors' reply (2020) (4)
A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS). (2016) (4)
A phase I pharmacokinetic study of PR-104, a hypoxia-targeting agent, in patients with solid tumors (2007) (3)
A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer (2004) (3)
A randomised controlled trial of clinical pharmacy intervention versus standard care to improve medication adherence in outpatients with head and neck cancer receiving radiotherapy (2022) (3)
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin (2022) (3)
A phase II trial of preoperative radiotherapy with protracted infusion 5-fluorouracil for resectable adenocarcinoma of rectum. A multi-center trial for the Trans-Tasman Radiation Oncology Group (2000) (3)
Prognostic Signiﬁcance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial (2010) (3)
The contribution of cytotoxic chemotherapy to the management of cancer. (2005) (3)
Correlation of HPV status and hypoxic imaging using [18F]-misonidazole (FMISO) PET in head and neck squamous cell carcinoma (HNSCC). (2011) (3)
Carboplatin dosing based on estimated Glomerular Filtration Rate (GFR) using IDMS creatinine: A comparison of estimated GFR based on IDMS creatinine in the Cockroft-Gault (CG) formula (IDMS-GFR), with measured GFR using 51Cr-EDTA (51Cr-GFR). (2015) (3)
Radiation oncology outpatient medication management needs and service gaps – A cross-sectional study of patients and clinicians (2019) (3)
585 First-in-man, Multicenter, Phase I Trial Evaluating the Safety of First-in-class Therapeutic, EGFR-targeted, Paclitaxel-Packaged Minicells (2012) (3)
Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2018) (3)
Comparison of bedside estimates of renal function and measured glomerular filtration rate (GFR) in 510 adult oncology patients (2007) (3)
Pseudotumor presentation of CMV disease: Diagnostic dilemma and association with immunomodulating therapy (2020) (3)
Pharmacodynamic studies of the specific oral EGFR tyrosine kinase inhibitor (EGFR-TKI) zd1839 (‘Iressa’) in skin from cancer patients participating in phase I trials: histopathological and molecular consequences of receptor inhibition (2001) (3)
Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up (2020) (3)
A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC) (2019) (3)
Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma (2021) (3)
Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma (2021) (3)
Symptom burden, quality of life, functioning and emotional distress in survivors of human papillomavirus associated oropharyngeal cancer: An Australian cohort. (2021) (3)
491 The prognostic significance of 18F-misonidazole (FMISO) PET-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with and without tirapazamine (2004) (2)
Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocol (2021) (2)
Prognostic significance of interleukin-8 (IL-8) and hepatocyte growth factor (HGF) in patients with head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on a phase III trial. (2010) (2)
Comparison of self-reported smoking status and physician-recorded smoking status among patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). (2011) (2)
Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors: Results from a phase I study (2001) (2)
Locoregional Radiation Therapy for De Novo Metastatic Nasopharyngeal Cancer: One Size Fits All? (2021) (2)
A Phase II Trial of Carboplatin and Etoposide for Relapsed or Metastatic Carcinoma of the Cervix (1998) (2)
Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study (2019) (2)
Differential Mechanisms of CDKN2A (p16) Inactivation in Oral Tongue Squamous Cell Carcinomas and Correlation With Patient Outcome (2014) (2)
Impact of p16 status on the QOL effects of chemoradiation for locally advanced oropharynx cancer: Results of TROG 02.02. (2012) (2)
INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2020) (2)
Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial (2020) (2)
Superiority of tirapazamine-containing chemoradiation in head and neck cancers showing evidence of hypoxia on 18F-misonidazole (FMISO) pet scanning. (2004) (2)
Surgical management of recurrent cutaneous squamous cell carcinoma of the head and neck after definitive surgery and radiotherapy. (2020) (2)
Chapter 47 – Management of Complications of Chemotherapy (2004) (2)
President Recent Work Title Quantitative and qualitative analysis of [ F-18 ] FDG and [ F-18 ] FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome (2018) (2)
Adjuvant chemotherapy and chemoradiation following surgery for high-risk endometrial cancer. (2010) (2)
Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) (2018) (2)
Impact of Prior Lines of Systemic Therapy (PST) on the Efficacy Of Cemiplimab, a Human Monoclonal Anti–PD-1, in Patients (PTS) with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) (2019) (2)
Delayed relapse following preoperative chemoradiation and surgery for rectal cancer (2003) (2)
A first-in-human, phase I pharmacodynamic (PD) and pharmacokinetic (PK) study of BNC105P, a novel vascular disrupting agent (VDA) and inhibitor of cancer cell proliferation. (2010) (2)
Contralateral neck failure in oral tongue cancer: Outcomes from two centers using predefined treatment criteria (2021) (2)
Prognostic stratification of HPV associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomised trials. (2022) (2)
Prognostic significance of plasma osteopontin in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on TROG 02.02 phase III trial. (2011) (1)
Recurrent intestinal type sinonasal adenocarcinoma treated with FOLFOX6 chemotherapy: Case report and review of literature (2012) (1)
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma (2018) (1)
Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas (2016) (1)
1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS] (2021) (1)
Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state. (2020) (1)
A phase I study of the vascular-disrupting agent BNC105P in combination with gemcitabine-carboplatin in platinum-sensitive ovarian cancer patients in first or second relapse. (2014) (1)
Promising New Approaches in the Treatment of Advanced Head and Neck Cancer (2003) (1)
The Changing Demography and Treatment of Nasopharyngeal Carcinoma in Melbourne from 1985–2000 (2003) (1)
Results of treatment intensification for progressive locoregional disease in head-and-neck cancer patients undergoing postoperative radiotherapy. (2005) (1)
P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009 (2021) (1)
Disparities starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274) (2019) (1)
Dose escalation study of concurrent carboplatin and fluorouracil with radical radiotherapy [RT] in non-small cell lung cancer (2000) (1)
Outcomes of curative (chemo)radiotherapy for patients with non‐p16 positive head and neck squamous cell carcinoma who are borderline for curative treatment (2020) (1)
789O Neoadjuvant cemiplimab in patients (pts) with stage II–IV (M0) cutaneous squamous cell carcinoma (CSCC): Primary analysis of a phase II study (2022) (1)
F-18 Fluorodeoxyglucose (FDG) PET and Indium-111 SPECT scans to track the biodistribution of macrophage-activated killer (MAK) cells linked with MDX-H210 in patients with epithelial ovarian cancer. (2004) (1)
Functional and molecular biomarker analysis demonstrates pharmacological activity for the novel vascular disrupting agent BNC105 in a first in human clinical study (2011) (1)
547 CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (2021) (1)
Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232. (2021) (1)
A Critical Review of 25 Years of Clinical Trials (1)
Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients treated with cetuximab and radiotherapy on TROG 12.01 and De-ESCALaTE randomized trials. (2021) (1)
1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results (2021) (1)
Molecular insights influencing the management of head and neck cancers (2015) (1)
PET response is the most powerful predictor of survival after radical radiotherapy/chemoradiotherapy for unresectable non-small cell lung cancer (2001) (1)
Transoral Surgery and Deintensified Adjuvant Therapy: Another Step in Determining Its Role in the Management of Human Papillomavirus Oropharyngeal Cancer. (2021) (1)
Radiation with cisplatin or carboplatin for locally advanced cervix cancer: The experience of a tertiary cancer center (2012) (1)
Treatment of hypercalcemia of malignancy with intermittent single infusions of 3-amino-1-hydroxypropylidene-1, 1-biphosphonate (APD) (1988) (1)
Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts (2018) (1)
A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug, in patients with solid tumors (2008) (1)
Relationship between epidermal growth factor receptor (EGFR) gene copy number, p16 status, and outcome in locally advanced squamous cell carcinoma of the head and neck (LASCCHN). (2010) (1)
Leptomeningeal metastases from anaplastic thyroid carcinoma. (2000) (1)
351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009 (2020) (1)
Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) (2017) (1)
Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome (2014) (1)
Discovery and clinical development of BNC105, a tubulin targeting small molecule that selectively disrupts the vasculature in solid tumours (2011) (1)
A phase I study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer (2007) (1)
263 POSTER Metabolism and pharmacokinetics of PR-104, a hypoxia-activated nitrogen mustard prodrug in phase I clinical trial (2006) (0)
Cutaneous squamous cell carcinoma metastatic to the axilla and groin: Outcomes and prognostic factors (2021) (0)
Update of Immune Therapies in Recurrent/Metastatic Head and Neck Cancer (2021) (0)
Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3 (2023) (0)
BRAF Inhibition in BRAF V 600 E-Positive Anaplastic Thyroid Carcinoma (2016) (0)
164 Phase 3 recurrent/metastatic cervical carcinoma trial: subgroup efficacy analysis of cemiplimab versus individual investigator’s choice chemotherapy (2021) (0)
Extradural malignancy simulating brachial neuritis. (1986) (0)
QOL for Advanced Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Randomized Trial of Tirapazamine, Cisplatin, and Radiation vs. Cisplatin and Radiation (TROG 02.02) (2009) (0)
In‐transit cutaneous squamous cell carcinoma (2022) (0)
Sexual Satisfaction and Relationship Status in Long-term Survivors of Human Papillomavirus-Associated Oropharyngeal Carcinoma (2019) (0)
1PDA high throughput compound screen identifies potential combinations to overcome resistance to Cdk2 inhibitors in Cyclin E1 amplified high grade serous ovarian cancer (2015) (0)
Reassessing Locus-Specific DNA Methylation in Head-and-Neck Squamous Cell Carcinoma (HNSCC) With Quantitative Methodology and Correlation With Patient Outcome (2014) (0)
An evaluation of health literacy in a consecutive sample of patients with cancer of the head and neck (H+N) region (2010) (0)
Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study. (2019) (0)
GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer. (2018) (0)
The negative predictive value of FDG PET/CT staging in early oropharyngeal squamous cell carcinoma and implications to transoral robotic surgery patient selection. (2022) (0)
P-88 First-Line Pembrolizumab With or Without Lenvatinib in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 3 LEAP-010 Study (2021) (0)
The "quad shot" - palliative radiotherapy in locally advanced head and neck squamous cell carcinoma (2005) (0)
A clinical trial with protracted infusion 5‐fluorouracil and mitomycin C for localized squamous cell carcinoma of the anus (2018) (0)
885TiP The I-PACE study: Imgatuzumab in PAtients with advanCEd cutaneous squamous cell carcinoma (aCSCC) (2022) (0)
Pharmacodynamic S tudies o f t he E pidermal G rowth F actor Receptor I nhibitor Z D1839 i n S kin F rom C ancer P atients: Histopathologic a nd M olecular C onsequences o f Receptor I nhibition (2002) (0)
The Current Treatment Landscape of Cutaneous Squamous Cell Carcinoma (2022) (0)
Prognostic and Predictive Signi fi cance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer (2012) (0)
An evaluation of health literacy (HL) in a consecutive sample of patients (pts) with cancer (ca) of the head and neck (H+N) region. (2010) (0)
High-Risk M erkel C ell C arcinoma o f t he S kin T reated W ith Synchronous C arboplatin/Etop oside a nd R adiation: A T rans- Tasman R adiation O ncology G roup S tudy—TROG 9 6:07 (2003) (0)
Quality of life and functioning in HPV associated oropharyngeal cancer survivors (2020) (0)
1087P Time to clinically meaningful changes in pain in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in a phase II clinical trial (2020) (0)
Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer (2022) (0)
Cemiplimab Improves Health-Related Quality of Life (HRQoL) and Reduces Pain in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Results from a Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial (2021) (0)
OC-0364: Impact of imaging and pathological biomarkers on survival after chemoradiation of locally advanced cervical cancer (2014) (0)
Drugging Tumour Hypoxia: Resolving the Complexity Using Functional Genetic Screens (2015) (0)
11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study (2020) (0)
A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours (2021) (0)
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. (2023) (0)
Feasibility of implementing a pharmacist-led DPYD gene testing service for patients commencing 5-fluorouracil (5FU) or capecitabine. (2021) (0)
Short communication Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced head and neck cancer (2000) (0)
A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer. (1992) (0)
EP-1087: Post treatment PET-CT to stratify follow-up for head and neck cancers - a matched cohort analysis of safety and cost (2014) (0)
PD-0822 Impact of radiotherapy laterality on patient-reported outcomes in T1-2 HPV tonsillar carcinoma (2022) (0)
P-603 Symptom response following high dose (HD) palliative radiotherapy (RT) plus concurrent weekly vinorelbine (V) and cis-platinum (C) in patients with locally advanced and metastatic non-small cell lung cancer (NSCLC): Results of a phase-I study (2003) (0)
GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-programmed death (PD)-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer (2020) (0)
373TiPKEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) (2017) (0)
Cancer Therapy : Preclinical Resistance toCDK 2 Inhibitors IsAssociatedwithSelection of Polyploid Cells in CCNE 1-Ampli fi ed Ovarian Cancer (2013) (0)
PA-01 : A Phase 2 , Multicenter , Double-Blind , Randomized , Vehicle Controlled Clinical Study to Assess the Synergistic Effect of a Halobetasol / Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis (2019) (0)
C-POST Protocol Update: A Phase 3, Randomized, Double-Blind Study of Adjuvant Cemiplimab vs. Placebo Post Surgery and Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma (2022) (0)
Survival With Cemiplimab in Recurrent Cervical Cancer (2022) (0)
Induction Chemotherapy in Head and Neck Cancer (2005) (0)
Weekly cisplatin and radiotherapy for low-risk human papillomavirus positive oropharyngeal squamous cell carcinoma (HPVOPC). (2014) (0)
PO-0791: Sexual health in HPV-related oropharyngeal cancer survivors after (chemo)radiotherapy (2020) (0)
Prognostic Signi fi cance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02 . 02 Phase III Trial (2011) (0)
Phase I study of docetaxel epirubicin and cyclophosphamide (TEC) in patients with advanced cancer (AC) (1999) (0)
Multi-Institutio nal R andomized P hase I I T rial o f G efitinib f or Previously T reated P atients W ith A dvanced N on-Small-Cell Lung C ancer (2003) (0)
973TiP LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (2020) (0)
The Clinical Impact of Hypoxia in Head and Neck Squamous Cell Carcinoma (2018) (0)
Gemcitabine for patients with relapsed nasopharyngeal carcinoma (2002) (0)
Analogues and Cytosine Arabinoside in Myeloid Leukemia Altered Multidrug Resistance Phenotype Caused by Anthracycline (2013) (0)
1105TiPPembrolizumab plus chemoradiation (CRT) for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Phase 3 KEYNOTE-412 trial (2017) (0)
Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Metastatic Cutaneous Squamous Cell Carcinoma (2018) (0)
Biomarkers for Immune Modulatory Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) (2021) (0)
Prognostic biomarkers in locally advanced cervical cancer (Cx Ca) treated with chemoradiation (CRT) (2016) (0)
Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy (2022) (0)
Use of 18F-HX4 PET/CT to estimate tumor hypoxia enrolled subjects from ongoing Phase 2 trials using tarloxotinib bromide in advanced NSCLC and SCCHN. (2016) (0)
Title Prognostic significance of plasma osteopontin in patients with loco-regionally advanced head and neck squamous cell carcinoma treated on TROG 02 . 02 Phase III trial (2011) (0)
CliniMACS CD34-selected cells to support high-dose therapy (2001) (0)
A phase I/II study of the vascular disrupting agent BNC105P in combination with gemcitabine-carboplatin in partially platinum-sensitive ovarian cancer patients in first or second relapse: An international collaborative group trial of ANZGOG and HOG. (2013) (0)
The utility of PET for the detection of disease in residual neck nodes following (chemo)radiotherapy in head and neck cancer (2004) (0)
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2022) (0)
List of Contributors (2019) (0)
Cancer Therapy : Clinical Clinical , Pharmacodynamic , and Pharmacokinetic Evaluation of BNC 105 P : A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation (2011) (0)
75 Can hypoxia imaging be used to identify patients for tirapazamine-based therapy? (2006) (0)
814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3 (2022) (0)
Phase I trial of gefitinib in combination with concurrent carboplatin, paclitaxel and radiation therapy (RT) in patients with stage III non-small-cell lung cancer (NSCLC) (2004) (0)
A Phase 3 randomized Double-blind Study of adjuvant Cemiplimab versus Placebo after Surgery and Radiotherapy for Patients with cutaneous squamous Cell Carcinoma Patients with high Risks (2020) (0)
Head and Neck Symptom Severity (HNSS) and Health-Related Quality of Life (HRQL) Trajectories during and after Chemoradiotherapy (CRT) for HPV-Associated Oropharyngeal Cancer (HPVOPC): A TROG 12.01 Secondary Analysis (2022) (0)
Abstract 4693: Characterization of the differential mechanisms ofCDKN2Ainactivation in oral tongue squamous cell carcinomas and correlation with patient outcome. (2013) (0)
Current Controversies in Cancer Does Biomodulation of 5-Fluorouracil Improve Results? (1999) (0)
659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048 (2022) (0)
818P Phase II confirmatory study of cemiplimab (350mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6 (2022) (0)
1259 Real world experience of immunotherapy in an elderly trial-ineligible cohort of patients with advanced cutaneous squamous cell carcinoma (2022) (0)
M OLECULAR INSIGHTS INFLUENCING THE MANAGEMENT OF HEAD AND NECK CANCERS (2015) (0)
Patient-report symptom severity, health-related quality of life and emotional distress trajectories during and after radiotherapy for HPV-associated oropharyngeal cancer: a XXXX.XXXX secondary analysis. (2023) (0)
Phase I study of repetitive high-dose topotecan (T) carboplatin (C) and paclitaxel (P) in previously untreated ovarian cancer (1999) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Danny Rischin?

Danny Rischin is affiliated with the following schools:

University of Texas Southwestern Medical Center
Chulalongkorn University
University of Queensland
Osaka Metropolitan University
MD Anderson Cancer Center
University of Oxford
University of Melbourne